Contrast Agents for MR Angiography: Current Status and Future Perspectives

[1]  G. Scotti,et al.  Carotid artery stenosis: intraindividual correlations of 3D time-of-flight MR angiography, contrast-enhanced MR angiography, conventional DSA, and rotational angiography for detection and grading. , 2005, Radiology.

[2]  M. Prokop,et al.  Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2005, Radiology.

[3]  Peter Boesiger,et al.  Improved three‐dimensional free‐breathing coronary magnetic resonance angiography using gadocoletic acid (B‐22956) for intravascular contrast enhancement , 2004, Journal of magnetic resonance imaging : JMRI.

[4]  C. Bremer,et al.  Index terms: Iron , 2022 .

[5]  H. P. Kang,et al.  Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. , 2004, Clinical chemistry.

[6]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[7]  J. Debatin,et al.  Peripheral vasculature: whole-body MR angiography with midfemoral venous compression--initial experience. , 2004, Radiology.

[8]  H. Kauczor,et al.  Time‐resolved contrast‐enhanced three‐dimensional pulmonary MR‐angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine , 2004, Journal of magnetic resonance imaging : JMRI.

[9]  P. Robinson,et al.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.

[10]  H. Kirchner,et al.  Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK 506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. , 2004, Clinical chemistry.

[11]  R. Weisskoff,et al.  MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial. , 2003, Radiology.

[12]  E. Nagel,et al.  Coronary arteries: contrast-enhanced MR imaging with SH L 643A--experience in 12 volunteers. , 2003, Radiology.

[13]  Knut Kröger,et al.  Comprehensive time-resolved MRI of peripheral vascular malformations. , 2003, AJR. American journal of roentgenology.

[14]  C. J. Doorenbos,et al.  Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. , 2003, The New England journal of medicine.

[15]  G. Marchal,et al.  Gadobenate Dimeglumine‐Enhanced Magnetic Resonance Angiography of the Pelvic Arteries , 2003, Investigative radiology.

[16]  C. Catalano,et al.  Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. , 2003, La Radiologia medica.

[17]  K. Kent,et al.  Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.

[18]  Martin Requardt,et al.  Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine , 2003, Journal of magnetic resonance imaging : JMRI.

[19]  J. Debatin,et al.  Using a 1 M Gd‐chelate (gadobutrol) for total‐body three‐dimensional MR angiography: Preliminary experience , 2003, Journal of magnetic resonance imaging : JMRI.

[20]  L. Cozzi,et al.  Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. , 2003, Radiology.

[21]  J. Debatin,et al.  Detection of atherosclerosis: systemic imaging for systemic disease with whole-body three-dimensional MR angiography--initial experience. , 2003, Radiology.

[22]  M. Taupitz,et al.  Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography , 2003, European Radiology.

[23]  M. Prince,et al.  MR venography: unsung and underutilized. , 2003, Radiology.

[24]  F. Floemer,et al.  Intraindividueller Vergleich dreier Kontrastmittel (Gd-DTPA, Gd-BOPTA und Gd-BT-DO3A) mit der multiphasischen MR-Angiographie , 2003, Der Radiologe.

[25]  J. Debatin,et al.  Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance Angiography , 2003, Investigative radiology.

[26]  Peter Boesiger,et al.  Performance of a new gadolinium‐based intravascular contrast agent in free‐breathing inversion‐recovery 3D coronary MRA , 2003, Magnetic resonance in medicine.

[27]  J. Meaney,et al.  Safety of contrast-enhanced MR angiography employing gadobutrol 1.0 M as contrast material , 2003, European Radiology.

[28]  G. Marchal,et al.  Gadobenate dimeglumine-enhanced MR angiography of the abdominal aorta and renal arteries. , 2002, AJR. American journal of roentgenology.

[29]  M. Bock,et al.  Assessment of Gadobenate Dimeglumine for Magnetic Resonance Angiography: Phase I Studies , 2002, Investigative radiology.

[30]  H. Schild,et al.  Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan®, (NC100150) for MRI of renal perfusion: Experimental study in an animal model , 2002, Journal of Magnetic Resonance Imaging.

[31]  J. Debatin,et al.  Whole-body three-dimensional MR angiography with a rolling table platform: initial clinical experience. , 2002, Radiology.

[32]  D. Leung,et al.  MR angiography of the renal arteries. , 2002, Radiologic clinics of North America.

[33]  E. Fleck,et al.  MR Coronary Angiography with the New Intravascular Contrast Agent B-22956/1: First Human Experience , 2002 .

[34]  J. Debatin,et al.  Optimization of Contrast Dosage for Gadobenate Dimeglumine-Enhanced High-Resolution Whole-Body 3D Magnetic Resonance Angiography , 2002, Investigative radiology.

[35]  D. Chassard,et al.  Safety and Pharmacokinetics of P792, a New Blood-Pool Agent: Results of Clinical Testing in Nonpatient Volunteers , 2002, Investigative radiology.

[36]  Peter Caravan,et al.  The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.

[37]  K. Scheffler,et al.  B22956/1, a new intravascular contrast agent for MRI: first administration to humans--preliminary results. , 2002, Academic radiology.

[38]  D. Bluemke,et al.  MRI detection of myocardial perfusion defects due to coronary artery stenosis with MS‐325 , 2002, Journal of magnetic resonance imaging : JMRI.

[39]  B. Hamm,et al.  Coronary magnetic resonance angiography: Experimental evaluation of the new rapid clearance blood pool contrast medium P792 , 2001, Magnetic resonance in medicine.

[40]  J. Debatin,et al.  0.5 M Gd chelate (Magnevist®) versus 1.0 M Gd chelate (Gadovist®): Dose‐independent effect on image quality of pelvic three‐dimensional MR‐angiography , 2001, Journal of magnetic resonance imaging : JMRI.

[41]  M. Kirchin,et al.  Safety assessment of gadobenate dimeglumine (MultiHance®): Extended clinical experience from phase I studies to post‐marketing surveillance , 2001, Journal of magnetic resonance imaging : JMRI.

[42]  J Lautrou,et al.  Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. , 2001, Investigative radiology.

[43]  M. Völk,et al.  Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. , 2001, Radiology.

[44]  J. Debatin,et al.  Rapid magnetic resonance angiography for detection of atherosclerosis , 2001, The Lancet.

[45]  T. Grist,et al.  Carotid MR angiography: phase II study of safety and efficacy for MS-325. , 2001, Radiology.

[46]  W. Heindel,et al.  Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. , 2001, Radiology.

[47]  M. Knopp,et al.  Einsatz von MR-Kontrastmitteln außerhalb der zugelassenen Anwendung (Off-label use) , 2001, Der Radiologe.

[48]  K. Scheffler,et al.  Optimization of Contrast-Enhanced MR Angiography of the Hands with a Timing Bolus and Elliptically Reordered 3D Pulse Sequence , 2000, Journal of computer assisted tomography.

[49]  T. Benner,et al.  Cerebral MR perfusion imaging: First clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double‐blinded randomized dose‐finding study , 2000, Journal of magnetic resonance imaging : JMRI.

[50]  G. R. Stevens,et al.  Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). , 2000, Investigative radiology.

[51]  J. Debatin,et al.  Equilibrium-phase MR angiography of the aortoiliac and renal arteries using a blood pool contrast agent. , 2000, AJR. American journal of roentgenology.

[52]  J. Debatin,et al.  MR-angiography: the role of contrast agents. , 2000, European journal of radiology.

[53]  M. Port,et al.  Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.

[54]  L. Calabi,et al.  Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. , 1999, Journal of computer assisted tomography.

[55]  René M. Botnar,et al.  Contrast agent‐enhanced, free‐breathing, three‐dimensional coronary magnetic resonance angiography , 1999, Journal of magnetic resonance imaging : JMRI.

[56]  S. Schoenberg,et al.  Diagnosis of renal vascular disease with MR angiography. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[57]  S. Schoenberg,et al.  Contrast agents for MRA: Future directions , 1999, Journal of magnetic resonance imaging : JMRI.

[58]  M. Knopp,et al.  Off‐label use and reimbursement of contrast media in MR , 1999, Journal of magnetic resonance imaging : JMRI.

[59]  T. Allkemper,et al.  Contrast‐enhanced 3D‐MRA of the upper abdomen with a bolus‐injectable SPIO (SH U 555 A) , 1999, Journal of magnetic resonance imaging : JMRI.

[60]  J Keegan,et al.  Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography , 1999, Journal of magnetic resonance imaging : JMRI.

[61]  J. Debatin,et al.  Optimization of contrast dosage for gadolinium-enhanced 3D MRA of the pulmonary and renal arteries. , 1998, Magnetic resonance imaging.

[62]  T L Chenevert,et al.  Magnetic resonance angiography with gadomer-17. An animal study original investigation. , 1998, Investigative radiology.

[63]  D C Peters,et al.  Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.

[64]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[65]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[66]  S. Saini,et al.  MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. , 1996, AJR. American journal of roentgenology.

[67]  P. Normann,et al.  Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.

[68]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.